Ansprechbarkeit von Drogengebrauchern über Infektionsrisiken für HIV und HCV

Opioidabhängigkeit und HIV-Infektion
Leitthema: HIV: Prävention und Aufklärung

Zusammenfassung

Von Beginn der HIV-Epidemie zählten drogenabhängige Menschen zur Hochrisikogruppe insbesondere dann, wenn sie Heroin injizierten. Bereits wenige Jahre nach Entdeckung des Hepatitis-C-Virus (HCV) war klar, dass die chronische Hepatitis C eine der größten Bedrohungen für Heroinabhängige ist. Die HIV-Prävalenz bei Heroinabhängigen beträgt in Deutschland 4–6 %, die HCV-Prävalenz liegt bei über 60 %. 90 % aller HIV-positiven Heroinabhängigen sind gleichzeitig auch HCVpositiv. Die HCV-Inzidenz ist vor allem bei jungen Drogenabhängigen sehr hoch. Präventiv wirksam sind besonders die Substitutionsbehandlung und die Nadelund Spritzenaustauschprogramme. Die Therapie einer HIV-Infektion und einer chronischen Hepatitis C ist während einer Substitutionsbehandlung am effektivsten und erfolgreichsten.

Schlüsselwörter

HIV-Infektion HCV-Infektion Heroin Substitutionsbehandlung Risikofaktoren 

Illegal drug users and risk factors for HIV and HCV infection

Abstract

Since the beginning of the HIV-epidemic, injection drug users (IDUs) have had a high risk of acquiring an infection with HIV. Chronic hepatitis C (HCV) is the most common infectious disease among IDUs. About 4 to 6 % of IDUs are HIV positive and more than 60 % are HCV positive. 90 % of HIV-positive IDUs are both HIV positive and HCV positive. Substitution treatment is the most effective prevention of HIV and HCV infection. Both HIV infection and chronic hepatitis C can be treated most successfully during substitution treatment.

Keywords

HIV infection HCV infection Heroin Substitution treatment Risk factors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Krausz M, Verthein U, Degkwitz P (1998) Prävalenz psychiatrischer Komorbidität bei opiatabhängigen Patienten. Nervenarzt 69:557–567PubMedCrossRefGoogle Scholar
  2. 2.
    EASL International Consensus Conference on Hepatitis C (1999) Consensus Statement. J Hepatol 30:956–961CrossRefGoogle Scholar
  3. 3.
    Backmund M, Meyer K, von Zielonka M, Eichenlaub D (2001) Treatment of Hepatitis C infection in injection drug users. Hepatology 34:188–193PubMedCrossRefGoogle Scholar
  4. 4.
    Backmund M, Meyer K, Henkel C et al. (2005) Risk factors and predictors of human immunodeficiency virus infection among injection drug users. Eur Addict Res 11:138–144PubMedCrossRefGoogle Scholar
  5. 5.
    UNAIDS (Joint United Nations Programme on HIV/ AIDS) (2006) 2006 Report on the Global AIDS Epidemic: A UNAIDS 10th anniversary special edition. UNAIDS, Geneva, SwitzerlandGoogle Scholar
  6. 6.
    Dehne KL, Khodakevich L et al. (1999) "The HIV/ AIDS epidemic in eastern Europe: recent patterns and trends and their implications for policymaking." AIDS 13(7):741–749PubMedCrossRefGoogle Scholar
  7. 7.
    National Institutes of Health Consensus Development Conference Panel Statement (1997) Management of Hepatitis C. Hepatology 26(Suppl): 71S–77SCrossRefGoogle Scholar
  8. 8.
    Backmund M, Meyer K, Wächtler M, Eichenlaub D (2003) Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 18:563–568PubMedCrossRefGoogle Scholar
  9. 9.
    Backmund M, Meyer K, von Zielonka (2001) Prävalenzdaten zu B und C bei Drogenabhängigen in München. Suchtmed 3:21–24Google Scholar
  10. 10.
    Sylvestre DL, Lottis J, Hauser P et al (2004) Cooccurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 81:719–734PubMedGoogle Scholar
  11. 11.
    Schäfer M, Schmidt F, Folwacnzy C et al. (2003) Adherence and mental side effects during hepatitis C treatment with inteferon alfa and ribavirin in psychiatric risk groups. Hepatology 37:443–451CrossRefGoogle Scholar
  12. 12.
    Hüllinghorst R (1993) Zur Versorgung Suchtkranker in Deutschland. In: Deutsche Hauptstelle gegen die Suchtgefahren (Hrsg) Jahrbuch Sucht 94. Neulandverlag, Geesthacht, S 23–37Google Scholar
  13. 13.
    Kraus L, Heppekausen K, Tretter F (2004) Prävalenzschätzungen von Opiatkonsumenten in deutschen Großstädten: Methoden und Ergebnisse. Sucht 50:11–20Google Scholar
  14. 14.
    Aceijas C, Stimson GV, Hickman M et al. (2004) Prevention and care among IDU in developing and transitional countries. AIDS 18:2295–2303PubMedCrossRefGoogle Scholar
  15. 15.
    Robert Koch Institut (2006) Epidemiol Bull 47: 411–426Google Scholar
  16. 16.
    Wiessing L, Roy K, Sapinho D et al. (2004) Surveillance of hepatitis C infection among injecting drug users in the European Union. In: Jager J, Kretschmar, M, Potsma M, Wiessing L (eds) Hepatitis C and injecting drug use: impact, costs and policy Z options. EMCDDA Monographs 7:91–135Google Scholar
  17. 17.
    Reimer J, Schulte B, Castells X et al. (2005) Guidelines for treatment of hepatitis C virus infection in injecting drug users: status quo in the European Union Countries. Clin Infect Dis 40(Suppl 5):S373–S378PubMedCrossRefGoogle Scholar
  18. 18.
    Conry-Cantilena C, VanRaden M, Gibble J et al. (1996) Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 334:1691–1696PubMedCrossRefGoogle Scholar
  19. 19.
    Chiaramonte M, Stroffolini T, Lorenzoni U et al. (1996) Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol 24:129–134PubMedCrossRefGoogle Scholar
  20. 20.
    Garfein RS, Doherty MC, Monterroso ER et al. (1998) Prevalence and incidence of hepatitis C virus infection among young adult injecting drug users. J Acquir Immune Defic Syndr Hum Retrovirol 18(Suppl 1):11S–19SGoogle Scholar
  21. 21.
    Nalpas B, Desenclos JC, Delarocque-Astagneau E, Drucker J (1998) State of epidemiological knowledge and national management of hepatitis C virus infection in the European Community, 1996. Eur J Public Health 8:305–312CrossRefGoogle Scholar
  22. 22.
    Backmund M, Reimer J, Meyer K et al. (2005) Hepatitis C and substance abuse: Treatment of IDUs. Clin Infect Dis 40(Suppl 5):S330–S335PubMedCrossRefGoogle Scholar
  23. 23.
    Backmund M, Hinrichsen H, Reimer J et al. (2006) Leitlinien der Deutschen Gesellschaft für Suchtmedizin (DGS e.V.): Therapie der chronischen Hepatitis C bei intravenös Drogengebrauchern. Suchtmed 8:131–133Google Scholar
  24. 24.
    Van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Coutinho RA (1993) A longitudinal study of the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 9:255–262PubMedCrossRefGoogle Scholar
  25. 25.
    Levine OS, Vlahov D, Brookmeyer R et al. (1996) Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users. J Infect Dis 173:579–583PubMedGoogle Scholar
  26. 26.
    Van Beek I, Dwyer R, Dore GJ et al. (1998) Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: a retrospective cohort study. BMJ 317:433–437PubMedGoogle Scholar
  27. 27.
    Brogly SB, Bruneau J, Vinclette J et al. (2000) Risk behaviour change and HIV infection among injection drug users in Montreal. AIDS 14:2575–2582PubMedCrossRefGoogle Scholar
  28. 28.
    Platt L, Bobraca N, Rhodes T et al. (2006) High HIV prevalence among injecting drug uses in Estonia: implications for understanding the risk environment. AIDS 20:2120–2123PubMedCrossRefGoogle Scholar
  29. 29.
    Offergeld R, Stark K, Hamouda O (2003) Transfusion relevant diseases in blood donors. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 46:775–779CrossRefGoogle Scholar
  30. 30.
    Dore GJ, Law M, MacDonald M, Kaldor JM (2003) Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 26:171–184PubMedCrossRefGoogle Scholar
  31. 31.
    Vlahov D, Junge B (1998) The role of needle exchange programs in HIV prevention. Public Health Rep 113(Suppl 1):75–80PubMedGoogle Scholar
  32. 32.
    Friedman SR, Jose B, Deren S et al. (1995) Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium. Am J Epidemiol 142:864–874PubMedGoogle Scholar
  33. 33.
    Johnson RA, Gerstein DR, Cerbone FG, Brown J (2002) HIV risk behaviors in African-American drug injector networks: implications of injection-partner mixing and partnership characteristics. Addiction 97:1011–1024PubMedCrossRefGoogle Scholar
  34. 34.
    Guadagnino V, Zimatore G, Izzi A et al. (1995) Relevance of intravenous cocaine use in relation to prevalence of HIV, hepatitis B and C virus markers among intravenous drug abusers in southern Italy. J Clin Lab Immunol 47:1–9PubMedGoogle Scholar
  35. 35.
    Bensley LS, Van Eenwyk J et al. (2000) Selfreported childhood sexual and physical abuse and adult HIV-risk behaviors and heavy drinking. Am J Prev Med 18(2):151–158PubMedCrossRefGoogle Scholar
  36. 36.
    Burke JG, Thiemann LK et al. (2005) Intimate partner violence, substance use, and HIV among lowincome women: taking a closer look. Violence Against Women 11(9):1140–1161PubMedCrossRefGoogle Scholar
  37. 37.
    Cohen M, Deamant C et al. (2000) Domestic violence and childhood sexual abuse in HIV-infected women and women at risk for HIV. Am J Public Health 90(4):560–565PubMedGoogle Scholar
  38. 38.
    Miller CL, Wood E et al. (2004) The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 36(2):743–749PubMedCrossRefGoogle Scholar
  39. 39.
    Miller M (1999) A model to explain the relationship between sexual abuse and HIV risk among women. AIDS Care 11(1):3–20PubMedCrossRefGoogle Scholar
  40. 40.
    El-Bassel N, Gilbert L et al. (2004) Deconstructing the relationship between intimate partner violence and sexual HIV risk among drug-involved men and their female partners. AIDS Behav 8(4):429–439PubMedCrossRefGoogle Scholar
  41. 41.
    Strathdee SA, Patrick DM et al. (1997) Social determinants predict needle-sharing behavior among injection drug users in Vancouver, Canada. Addiction 92(10):1339–1347PubMedCrossRefGoogle Scholar
  42. 42.
    Dube SR, Felitti VJ, Dong M et al. (2003) Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study. Pediatrics 111:564–572PubMedCrossRefGoogle Scholar
  43. 43.
    Hagan H, Mc Gough JP, Thiede H et al. (1999) Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 149:203–213Google Scholar
  44. 44.
    Mansson AS, Moestrup T, Nordenfelt E, Widell A (2000) Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 32(3):253–258PubMedCrossRefGoogle Scholar
  45. 45.
    Haltmayer H, Schmidt R, Strobel S (2000) Qualitätscheck – Untersuchungen über den i.v. Konsum illegaler Drogen mittels Analyse von gebrauchten Injektionsspritzen. Suchtmed 2(Suppl 1):285Google Scholar
  46. 46.
    Hagan H, Thiede H, Weiss NS et al. (2001) Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91:42–46PubMedCrossRefGoogle Scholar
  47. 47.
    Hahn JA, Page-Shafer K, Lum PJ et al. (2002) Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 186:1558–1564PubMedCrossRefGoogle Scholar
  48. 48.
    Gowing LR, Farrell M, Bornemann R, Ali R (2004) Substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane Database of Systematic Reviews 4:CDoo4145Google Scholar
  49. 49.
    Gowing LR, Farrell M, Borneman R et al. (2005) Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 20:1–3CrossRefGoogle Scholar
  50. 50.
    Backmund M, Meyer K (2006) Hepatitis-C-Therapie während der Substitutionsbehandlung. Suchtmed 8:115–118Google Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  1. 1.Klinikum SchwabingMünchenBRD
  2. 2.Bereich SuchtmedizinKlinikum SchwabingMünchenBRD

Personalised recommendations